Massimiliano Camilli
Massimiliano Camilli is an expert in Cardiology at Agostino Gemelli University Polyclinic (Italy). Massimiliano Camilli has authored 146 publications, the most recent in 2026, and is an investigator in 1 clinical trial, 1 of them ongoing. SLR score: 542 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Oncology - Pharmacy - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2019 - 2026
Number : 146
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Rationale and Design of the CARdio-Tox Study: A Prospective Evaluation of Cardiovascular Toxicity in Patients Receiving Chimeric Antigen Receptor-T (CAR-T) Cell Therapy. PMID 42841810 — cells, cytokine release syndrome, biomarkers, receptors, antigen, receptors, chimeric antigen, therapeutics, t-lymphocytes, car-t cell | J Cardiovasc Pharmacol | 2026 | 0 |
| Refining cardiovascular pharmacotherapy in cardio-oncology and cardiac amyloidosis: news from ESC Congress 2026. PMID 42839776 — drug therapy, amyloidosis, cardio-oncology | Eur Heart J Cardiovasc Pharmacother | 2026 | 0 |
| Long-term outcomes of transcatheter mitral valve repair in patients with cancer: a systematic review and meta-analysis. PMID 42786380 — comorbidity, mortality, mitral valve, heart failure, heart, aging, neoplasms, aged, therapeutics, mitral valve insufficiency | Geroscience | 2026 | 0 |
| Strategies for preventing and reversing atrial cardiomyopathy (AtCM): current evidence, therapeutic targets, and future directions. A European Journal of Heart Failure expert consensus statement. PMID 42617069 — fibrosis, heart failure, heart, atrial fibrillation, therapeutics, catheter ablation, cardiomyopathies | Eur J Heart Fail | 2026 | 0 |
| Bruton tyrosine kinase inhibitors and cardiovascular adverse events. PMID 42529945 — leukemia, lymphocytic, chronic, b-cell, drug therapy, drug-related side effects and adverse reactions, pharmacology, cardiotoxicity, protein-tyrosine kinases, agammaglobulinaemia tyrosine kinase, tyrosine, therapeutics | Br J Pharmacol | 2026 | 0 |
Clinical Studies 1
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies NCT06664528 — laboratories, troponin, neoplasms, troponin i, biomarkers, natriuretic peptide, brain, cardiotoxicity, echocardiography, natriuretic peptides, therapeutics, prognosis, electrocardiography, cardio-oncology | N/A | Recruiting | 2025 |
LeadR Networks
Main global connection map